Change of apheresis device decreased the incidence of severe acute graft‐versus‐host disease among patients after allogeneic stem cell transplantation with sibling donors

Wang, T.; Remberger, Mats; Nygell, Ulla Axdorph; Sundin, Mikael; Björklund, Andreas; Mattsson, Jonas; Uhlin, Michael; Watz, Emma

doi:10.1111/trf.14579

Cited by 5 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The single-day apheresis procedure was performed using the Spectra Optia apheresis system (Terumo BCT, Inc., Lakewood, CO, USA) after 4 days of stem cell mobilization in which the donor received daily administration of recombinant human granulocyte colony-stimulating factor (G-CSF, filgrastim, Amgen, Thousand Oaks, CA, USA) at a dose of 10 μg/kg. More details on the apheresis procedure can be found in an earlier publication from our center by Wang et al (17). Post-collection processing the following day included negative depletion of αβ T-cells using the CliniMACS system (Miltenyi Biotech, Bergisch Gladbach, Germany) as previously published (14) with the exception that no B-cell depletion was performed in our setup.…”

Section: Methodsmentioning

confidence: 99%

Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion

et al. 2019

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with several potentially lethal complications. Higher levels of CD3+ T-cells in the graft have been associated with increased risk of graft-versus-host disease (GVHD), but also beneficial graft-versus-leukemia effect and reduced infections. To tackle post-transplant complications, donor lymphocyte infusions have been used but with an increased risk of GVHD. To reduce this risk, we performed depletion of αβ T-cells and treated 12 patients post-HSCT suffering from infections and/or poor immune reconstitution. The αβ T-cell depleted cell products were characterized by flow cytometry. The median log depletion of αβ T-cells was −4.3 and the median yield of γδ T-cells was 73.5%. The median CD34+ cell dose was 4.4 × 106/kg. All 12 patients were alive 3 months after infusion and after 1 year, two patients had died. No infusion-related side effects were reported and no severe acute GVHD (grade III-IV) developed in any patient post-infusion. Overall, 3 months after infusion 11 out of 12 patients had increased levels of platelets and/or granulocytes. In conclusion, we describe the use of αβ T-cell depleted products as stem cell boosters with encouraging results.

show abstract

Section: Methodsmentioning

confidence: 99%